Seval Yildiz Sahin, Turkan Pasali Kilit, Fatma Emel Kocak


Background: In hyperthyroidism, oxidative stress is produced due to an increase in the production of reactive oxygen species as a result of the hypersecretion of thyroid hormone. The objectives of this study were to determine the effect of methimazole on three oxidative stress markers in patients with hyperthyroidism in the population of Kutahya City, Turkey.

Materials & Methods: This quasi-experimental study was conducted in Faculty of Medicine, Kutahya Health Sciences University, Kutahya, Turkey from August 2020 to September 2021. Thirty newly diagnosed hyperthyroidism patients were included. Methimazole treatment was given to all patients for three months. Two patients were dropped due to allergic reactions. Total antioxidant status (TAS) and total oxidant status (TOS) were measured, and oxidative stress index (OSI) was calculated at the time of diagnosis and after three months of methimazole treatment. All data was analyzed by mean and SD with 95%CI. Three hypotheses were verified by paired samples t test.

Results: In a sample of 30 hyperthyroidism patients, mean TAS level was 1.52 mmol Trolox Eq/L before treatment. It increased significantly to 1.58 with methimazole treatment (p=.013). Mean TOS level was 10.40 μmol H2O2 Eq/L before treatment. It decreased significantly to 6.79 with methimazole treatment (p=<.0001). Mean OSI level was 0.68 arbitrary units before treatment. It decreased significantly to 0.44 with methimazole treatment (p=<.0001).

Conclusion: Methimazole drug treatment for three months for hyperthyroidism increased total antioxidant status, while decreased total oxidant status and oxidative stress index in population of Kutahya City, Turkey.


Hyperthyroidism; Total Oxidant Status; Total Antioxidant Status; Oxidative Stress Index; Methimazole; Oxidative Stress; Graves’ Disease; Goiter; Thyroiditis.

Full Text:



Oncel M, Kıyıcı A, Onen S. Evaluation of the relationship between ischemia-modified albumin levels and thyroid hormone levels. J Clin Lab Anal 2015;29(6):427-31. https://doi.org/10.1002/jcla.21789

Bednarek J, Wysocki H, Sowiński J. Oxidative stress peripheral parameters in Graves' disease: the effect of methimazole treatment in patients with and without infiltrative ophthalmopathy. Clin Biochem 2005;38(1):13-8. https://doi.org/10.1016/j.clinbiochem.2004.09.015

Mishra P, Samanta L. Oxidative stress and heart failure in altered thyroid states. Scientific World J 2012;2012:741861. https://doi.org/10.1100/2012/741861

Marcocci C, Leo M, Altea MA. Oxidative stress in Graves' disease. Eur Thyroid J 2012; 1(2):80-7. https://doi.org/10.1159/000337976

Mancini A, Di Segni C, Raimondo S, Olivieri G, Silvestrini A, Meucci E, et al. Thyroid hormones, oxidative stress, and inflammation. Mediators Inflamm 2016;2016:6757154. https://doi.org/10.1155/2016/6757154

Verma M, Dahiya K, Ghalaut VS, Soni A, Singh J, Dhupper V. Comparative study of ischemia modified albumin and nitric oxide in hyperthyroidism. J Invest Biochem 2014;1(1):17-20. https://doi.org/10.5455/jib.20130707090209

Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J 2018;7(4):167-86. https://doi.org/10.1159/000490384

Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37(2):112-9. https://doi.org/10.1016/j.clinbiochem.2003.10.014

Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38(12):1103-11. https://doi.org/10.1016/j.clinbiochem.2005.08.008

Andryskowski G, Owczarek T. The evaluation of selected oxidative stress parameters in patients with hyperthyroidism. Polskie Archiwum Medycyny Wewnetrznej 2007;117(7):285-9. https://doi.org/10.20452/pamw.158

Kocak M, Akarsu E, Korkmaz H, Taysi S. The effect of antithyroid drugs on osteopontin and oxidative stress in Graves' disease. Acta Endocrinol (Buchar) 2019;15(2):221-4. https://doi.org/10.4183/aeb.2019.221

Saleh AAS. Lipid profile and levels of homocysteine and total antioxidant capacity in plasma of rats with experimental thyroid disorders. J Basic App Zool 2015;72:173-8. https://doi.org/10.1016/j.jobaz.2015.01.001

Komosinska-Vassev K, Olczyk K, Kucharz EJ, Marcisz C, Winsz-Szczotka K, Kotulska A. Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves' disease during therapy. Clin Chim Acta 2000;300(1-2):107-17. https://doi.org/10.1016/S0009-8981(00)00306-5

Aslan M, Cosar N, Celik H, Aksoy N, Dulger AC, Begenik H, et al. Evaluation of oxidative status in patients with hyperthyroidism. Endocrine 2011;40(2):285-9. https://doi.org/10.1007/s12020-011-9472-3

Erdamar H, Demirci H, Yaman H, Erbil MK, Yakar T, Sancak B, et al. The effect of hypothyroidism, hyperthyroidism, and their treatment on parameters of oxidative stress and antioxidant status. Clin Chem Lab Med 2008;46:1004-10. https://doi.org/10.1515/CCLM.2008.183

Bednarek J, Wysocki H, Sowinski J. Oxidation products and antioxidant markers in plasma of patients with Graves' disease and toxic multinodular goiter: effect of methimazole treatment. Free Radic Res 2004;38(6):659-64. https://doi.org/10.1080/10715760410001701621

Guerra LN, Moiguer S, Karner M, de Molina MC, Sreider CM, Burdman JA. Antioxidants in the treatment of Graves' disease. IUBMB Life 2001;51(2):105-9. https://doi.org/10.1080/15216540117362

Abalovich M, Llesuy S, Gutierrez S, Repetto M. Peripheral parameters of oxidative stress in Graves' disease: the effects of methimazole and 131 iodine treatments. Clin Endocrinol (Oxf) 2003;59(3):321-7. https://doi.org/10.1046/j.1365-2265.2003.01850.x

Leo M, Bartalena L, Rotondo Dottore G, Piantanida E, Premoli P, Ionni I, et al. Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial. J Endocrinol Invest 2017;40(3):281-7. https://doi.org/10.1007/s40618-016-0559-9

DOI: https://doi.org/10.46903/gjms/20.03.1063


  • There are currently no refbacks.

Copyright (c) 2022. Seval Yildiz Sahin, Turkan Pasali Kilit, Fatma Emel Kocak.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.